CStone Confirms Significant Efficacy in Interim Analysis of Final Analysis of Zejimei's Phase III Non-Small Cell Lung Cancer Registration Study

On May 17, CStone Pharmaceuticals (261HK), a Hong Kong-based innovative pharmaceutical company, announced that the potential best-in-class drug Zejima® (sugalimab injection) as a consolidation therapy showed no disease progression after concurrent or sequential chemoradiotherapy Results of a prespecified final analysis of progression-free survival (PFS) from a registrational clinical trial (GEMSTONE-301 study) in patients with unresectable, unresectable stage III non-small cell lung cancer (NSCL.

This means that Zejimet® is the world's first PD(L)-1 mAb to significantly improve progression-free survival in stage III NSCLC patients without disease progression after concurrent or sequential chemoradiothera.

Professor Wu Yilong, the principal investigator of the GEMSTONE-301 study and the tenured director of Guangdong Provincial People's Hospital, said that compared with the excellent data in the interim analysis of PFS last year, in the final analysis of PFS this time, Zejiemei® was used as a consolidation treatme.

Jianxin Yang, .

It is worth mentioning that The Lancet Oncology, the world's top clinical tumor research journal, published two registration clinical research data of Zejimei® in the same period in January 2022, from GEMSTONE-301 and GEMSTONE-301 respective.

In addition, Zejimet® has also made breakthroughs in the expansion of new indicatio.